Fate Therapeutics, Inc. Share Price & Technical Analysis
FATE · $2.42 (-5.84%)
Healthcare / Biotechnology
$2.42
-5.84%
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. …
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-7% return in Jun, -11% avg return in past 3 year Jun month.
157% return in 2026, -25% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 20% | 25% | -14% | 0% | 133% | -7% | – | – | – | – | – | – | 157% |
| 25 | -24% | -15% | -27% | 63% | -8% | -15% | 0% | -9% | 30% | 17% | -21% | -9% | -20% |
| 24 | 68% | 15% | 1% | -45% | -7% | -11% | 61% | -30% | -5% | -31% | 33% | -48% | -2% |
| 23 | -39% | 3% | -8% | 9% | -16% | -6% | -15% | -39% | -16% | -14% | 39% | 48% | -54% |
| 22 | -29% | -18% | 10% | -26% | -19% | 8% | 22% | -13% | -13% | -9% | -4% | -52% | -143% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$308.30M
P/E ratio
—
52W high
$2.88
52W low
$0.91
Volume
5,63,441
Beta
2.14
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Fate Therapeutics, Inc. share price today?
- Fate Therapeutics, Inc. (FATE) last traded around $2.42 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does FATE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for FATE. Download the app for real-time alerts.
- How can I analyze Fate Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.